Drug Trial Radar · NCT07869953
Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 7, 2024
Primary completion
Mar 25, 2025
Study completion Mar 25, 2025
Sponsor
- Lead sponsor
- BioNanoSim Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are: 1. Are adverse events observed during the treatment period and if so, what are their severity? 2. What is the change in Best Corrected Visual Acuity (BCVA) test using the Early Treatment Diabetic Retinopathy Study (ETDRS) acuity chart from baseline to Day 29? 3. What is the change in Intraocular Pressure (IOP) from baseline to Day 29? The expected study duration for each patient will be up to 6 weeks including up to 1 week for screening, a 4-week treatment period and a 1-week safety follow-up period. Patients will be administered Oftac 0.05% eye drops four (4) times every day, for up to six weeks.
Conditions
- Non-Infectious Anterior Uveitis
Interventions
Oftac: 0.05% tacrolimus ophthalmic emulsionDrug
Oftac 0.05% eye drops administered as a single drop four (4) times every day (QID) as a monotherapy in patients not currently being administered another treatment, or as an add-on therapy to an existing therapeutic regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: 6 weeks
- Change in Best Corrected Visual Acuity (BCVA)Time frame: 6 weeks
- Change in Intraocular Pressure (IOP)Time frame: 6 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Department of Ophthalmology, Soroka University Medical Center, Ben-Gurion University of the Negev
Beersheba, Israel
Department of Ophthalmology, Bnai Zion Medical Center
Haifa, Israel
Department of Ophthalmology, Carmel Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology
Haifa, Israel
Department of Ophthalmology, Rambam Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology
Haifa, Israel
Department of Ophthalmology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem
Jerusalem, Israel
Department of Ophthalmology, Rabin Medical Center
Petah Tikva, Israel
Shamir Medical Center
Tsrifin, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.